Alterity Therapeutics Limited Stock
Stocks
ATH
AU0000043945
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5900 AUD | 0.00% |
|
-7.09% | +47.50% |
| Market Cap | 89.61M 78.31M 72.26M 66.61M 126M 8.63B 128M 864M 340M 4.23B 337M 329M 14.55B | P/E 2026 * |
-0.35x | P/E 2027 * | -0.34x |
|---|---|---|---|---|---|
| Enterprise Value | 44.42M 38.82M 35.82M 33.02M 62.23M 4.28B 63.62M 428M 168M 2.1B 167M 163M 7.21B | EV / Sales 2026 * |
17.3x | EV / Sales 2027 * | 40.6x |
| Free-Float |
91.76% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Limited
| 1 week | -7.09% | ||
| Current month | +2.61% | ||
| 1 month | +2.61% | ||
| 3 months | +18.00% | ||
| 6 months | +47.50% | ||
| Current year | +47.50% |
| 1 week | 0.56 |  | 0.64 |
| 1 month | 0.56 | | 0.78 |
| Current year | 0.35 | | 0.78 |
| 1 year | 0.35 | | 0.85 |
| 3 years | 0.1 | | 0.95 |
| 5 years | 0.1 | | 1.9 |
| 10 years | 0.1 | | 20.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Niven
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 15/6/26 | Free | Director | 1,000,000 | 0.0092% | ||
| 15/6/26 | Free | Director | 1,000,000 | 0.0092% | ||
| 15/6/26 | Free | Chairman | 2,000,000 | 0.0184% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -7.09% | -9.23% | +68.57% | 89.61M | |
| +3.90% | -0.39% | +376.72% | +599.59% | 39.58B | |
| -1.70% | +4.46% | +7.46% | +57.67% | 34.69B | |
| -2.01% | -0.76% | +26.35% | -6.83% | 34.42B | |
| +0.06% | +0.34% | +2.32% | +29.30% | 27.11B | |
| +0.46% | -3.49% | - | - | 16.21B | |
| -0.04% | -0.09% | +68.48% | +117.39% | 15.36B | |
| +1.12% | +1.91% | +15.90% | +19.65% | 14.05B | |
| 0.00% | +1.36% | +15.74% | -30.62% | 13.02B | |
| -0.08% | -3.01% | +1,271.69% | +649.69% | 11.76B | |
| Average | +0.17% | -0.68% | +197.27% | +167.15% | 20.63B | |
| Weighted average by Cap. | +0.24% | +0.35% | +171.35% | +187.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.57M 2.24M 2.07M 1.91M 3.6M 247M 3.68M 24.76M 9.74M 121M 9.65M 9.43M 417M | 1.2M 1.05M 968K 892K 1.68M 116M 1.72M 11.57M 4.55M 56.61M 4.51M 4.41M 195M |
| Net income | -14.64M -12.8M -11.81M -10.88M -20.52M -1.41B -20.97M -141M -55.51M -691M -54.99M -53.79M -2.38B | -29.66M -25.92M -23.92M -22.05M -41.55M -2.86B -42.48M -286M -112M -1.4B -111M -109M -4.82B |
| Net Debt | -45.19M -39.49M -36.44M -33.59M -63.31M -4.35B -64.71M -436M -171M -2.13B -170M -166M -7.34B | -40.88M -35.73M -32.97M -30.39M -57.27M -3.94B -58.55M -394M -155M -1.93B -154M -150M -6.64B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | $0.5900 | 0.00% | 33,706 |
| 16/07/26 | $0.5900 | +2.61% | 51,964 |
| 15/07/26 | $0.5750 | -4.17% | 122,884 |
| 14/07/26 | $0.6000 | -5.51% | 346,778 |
| 13/07/26 | $0.6350 | 0.00% | 59,304 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
